2021
Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment
Tymon-Rosario J, Adjei NN, Roque DM, Santin AD. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment. Cancers 2021, 13: 6239. PMID: 34944858, PMCID: PMC8699494, DOI: 10.3390/cancers13246239.Peer-Reviewed Original ResearchEpithelial ovarian cancerOvarian cancerClinical dataEpithelial ovarian cancer treatmentTaxane-treated patientsUse of ixabepiloneRefractory ovarian cancerOngoing clinical trialsStandard of careOvarian cancer treatmentClinical trialsRecurrent treatmentTaxane resistanceCurrent standard practiceChemotherapeutic agentsTherapeutic agentsCancerCancer treatmentPutative mechanismsMicrotubular functionTreatmentDrugs partTaxanesCell deathCurrent useNovel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer
Mauricio D, Harold J, Tymon-Rosario JR, Zeybek B, Santin AD. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer. Expert Opinion On Biological Therapy 2021, 21: 1087-1096. PMID: 33356644, DOI: 10.1080/14712598.2021.1869210.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesOvarian cancerProgressive diseaseFavorable adverse effect profilePromising novel therapeutic agentAdverse effect profilePhase II trialDeadliest gynecologic malignancyPhase III dataNovel therapeutic agentsII trialGynecologic malignanciesEffect profileClinical resultsEffective therapyAvailable agentsCurrent evidenceNovel treatmentsChemotherapeutic agentsCancerTherapeutic agentsAdverse effectsMesothelinVivo dataDisease
2016
Improved i.p. drug delivery with bioadhesive nanoparticles
Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen M, Bellone S, Santin AD, Saltzman WM. Improved i.p. drug delivery with bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 11453-11458. PMID: 27663731, PMCID: PMC5068292, DOI: 10.1073/pnas.1523141113.Peer-Reviewed Original ResearchConceptsChemotherapeutic agentsUterine serous carcinoma patientsBioadhesive nanoparticlesAdministration of chemotherapySerous carcinoma patientsPotent chemotherapeutic agentPeritoneal carcinomatosisCarcinoma patientsPeritoneal spaceAbdominal cavityLow systemic toxicityLymphatic drainageTherapeutic efficacyMesothelial cellsHigh therapeutic efficacySystemic toxicityFast clearanceEfficacy of nanoparticlesEfficacyFree EBBiodegradable nanoparticlesNanoparticlesDrug deliveryCarcinomatosisChemotherapy
2014
Taxanes
Schwab CL, English DP, Roque DM, Santin AD. Taxanes. Anti-Cancer Drugs 2014, 25: 522-535. PMID: 24300913, PMCID: PMC3980024, DOI: 10.1097/cad.0000000000000057.Peer-Reviewed Original ResearchConceptsTaxane-based chemotherapyUse of taxanesGynecologic cancerRoute of treatmentRadiation sensitizing propertiesGynecologic malignanciesCervical cancerEffective therapyTreatment intervalAppropriate doseResponse rateNew treatmentsChemotherapeutic agentsTaxanesCancerSensitizing propertiesChemotherapyTreatmentActive agentsMalignancyDocetaxelOvarianTherapyAgentsDose